Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No

Executive Summary

The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.

Related Content

Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move
Stand-Off: Vertex Refuses NICE Data on CF Drug Symkevi, HTA Body Awaits Next Move
Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro
Portola's Rocky Commercial Transition On Show In Q2, With No CEO
EU Accelerated Assessment Tracker: EMA To Fast Track Thalassemia Gene Therapy, New HIV Drug
EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold
EU-Wide Restrictions In Store For Bayer's Prostate Cancer Drug
Radius Braced For Second CHMP No For Abaloparatide
Crunch Time For 18 Products Seeking EU Approval, "No" Stays In Place for Radius
EU Accelerated Assessment Tracker: Rejection Is Standard Outcome For Fast-Track Requests This Year





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts